Newsletter | April 22, 2025

04.22.25 -- March 2025 — CDMO Opportunities And Threats Report

SPONSOR

Take a tour of Nanoform's best-in-class nanodevelopment capabilities, setting new standards in innovation. Their highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs. With 14 development lines for small molecules and 5 for large molecules, Nanoform offers unmatched scalability and precision. Leveraging cutting-edge technology, they produce nanoformed materials as small as 10 nanometers. Learn more

FOCUS ON OUTSOURCING

March 2025 — CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Getting To The Heart Of CDMO Tech Transfer Excellence

Discover five key factors that drive a seamless and efficient technology transfer. Learn why a culture of technical expertise, customer focus, and operational flexibility is key to CDMO success.

Application Of Plant And Process Models

Explore innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.

How An End-To-End CDMO Simplifies And Speeds Drug Development

Access to technical, process, and regulatory experts under one CDMO roof minimizes logistical and cost-related concerns for biopharma companies while offering them unprecedented control over production.

Enabling Research Advances Worldwide

Service expectations for life science customers have evolved. Discover a service solution that offers a comprehensive partnership, providing proactive maintenance, expert guidance, and continuous support.

Key Analytical Considerations For Developing A Clinical AAV Program

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

Secure Tech Transfers Of Biological Products In Sterile Manufacturing

Recognizing what it takes to complete technology transfers effectively and efficiently is crucial to selecting the best partner for your project and product needs.

Streamline The Path To FIH Trials With Advanced Cell Line Development

Many CDMOs cannot handle complex recombinant proteins, which often require a CLD process fully integrated with other CDMO components, including analytics and formulation development.

SPONSOR

Multispecific molecules bring added complexity to downstream purification—think incorrect chain pairings, aggregation, fragmentation, and lower yields. Join Bioprocess Online Live as we explore how developers are addressing these challenges to achieve high purity and efficient processes. Gain insights into key considerations for downstream teams when designing purification strategies for these advanced biologics. Registration is free thanks to the support of Thermo Fisher Scientific.

OUTSOURCING SOLUTIONS

Developability For Complex Biologics And Bioconjugates - Abzena

End-to-End CDMO Solutions For CGT Success - GC Cell

Ramp Up Your AAV Production With The Xcite AAV Platform Technology - Lonza

Capacity Update July 2024: Large Molecule Development - Aton Biotech

Connect With Bioprocess Online: